Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets

Status Completed

Clinical Trial Summary

This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH).

Clinical Trial Description

This protocol is designed to assess both acute and chronic effects of the calcium channel antagonist, nifedipine, on the hypothalamic-pituitary-adrenal axis in patients with congenital adrenal hyperplasia. The multicenter trial is composed of two phases and will involve a double-blind, placebo-controlled parallel design. The goal of Phase I is to examine the ability of nifedipine vs. placebo to decrease adrenocorticotropic hormone (ACTH) levels, as well as to begin to assess the dose-dependency of nifedipine effects. The goal of Phase II is to evaluate the long-term effects of nifedipine; that is, can attenuation of ACTH release by nifedipine permit a decrease in the dosage of glucocorticoid needed to suppress the HPA axis? Such a decrease would, in turn, reduce the deleterious effects of glucocorticoid treatment in CAH. ;

Study Design

Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00000102
Study type	Interventional
Source	National Center for Research Resources (NCRR)
Contact
Status	Completed
Phase	Phase 1/Phase 2

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03687242` - Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia	Phase 2
Active, not recruiting	`NCT04544410` - A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH	Phase 2
Not yet recruiting	`NCT04087148` - Linear Growth of Children With Congenital Adrenal Hyperplasia
Completed	`NCT03162159` - Adult Height Prediction in Congenital Adrenal Hyperplasia
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Enrolling by invitation	`NCT05162950` - Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH
Withdrawn	`NCT03532022` - Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy	Phase 3
Recruiting	`NCT02795871` - Prenatal Dex Study	N/A
Completed	`NCT02934399` - Dynamic Hormone Diagnostics in Endocrine Disease
Recruiting	`NCT04903587` - Gonadal Changes In Congenital Adrenal Hyperplasia Patients
Not yet recruiting	`NCT04536662` - Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency	Phase 4
Recruiting	`NCT04463316` - GROWing Up With Rare GENEtic Syndromes
Active, not recruiting	`NCT04490915` - Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia	Phase 3
Completed	`NCT01807364` - Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia	N/A
Completed	`NCT02804178` - A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia	Phase 2
Completed	`NCT03019614` - An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone	Phase 1
Not yet recruiting	`NCT04293133` - Final Height in Patients With CAH
Recruiting	`NCT03897504` - Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty	N/A
Recruiting	`NCT05663320` - A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia	N/A
Active, not recruiting	`NCT04806451` - Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)	Phase 3